# US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

> **NCT00282295** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1344 (actual)

## Conditions studied

- Acellular Pertussis
- Tetanus
- Diphtheria

## Interventions

- **BIOLOGICAL:** Boostrix®
- **BIOLOGICAL:** Menactra™

## Key facts

- **NCT ID:** NCT00282295
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-25
- **Primary completion:** 2006-08-08
- **Final completion:** 2006-08-08
- **Target enrollment:** 1344 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00282295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00282295, "US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00282295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*